Page 26 - Syncona Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Quell Therapeutics Expands Series A Financing to $84 Million Search jobs Quell Therapeutics Expands Series A Financing to $84 Million – Largest Series A in the Treg field –       London, UK – February 11 2021 – Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd (“Syncona”), who have committed an additional $34.7 million and UCL Technology Fund (“UCLTF”) who have committed an additional $1 million; br...

Investegate announcements from Syncona Limited, Achilles announces additional financing plans

05 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned.  The fu...

Syncona Appoint Virginia Holmes as Non-Executive Director 7:33 am Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, has announced the appointment of Virginia Holmes as a Non-Executive Director with effect from 1 January 2021. Virginia has extensive knowledge of the financial services industry including investment management and banking. She was previously Chief Executive of AXA Investment Managers UK and held a number of senior leadership roles over more than a decade at Barclays Bank G...

Press release content from Business Wire. The AP news staff was not involved in its creation. Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases December 18, 2020 GMT LONDON--(BUSINESS WIRE)--Dec 18, 2020-- Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapie...